|Mode of transmission||Airborne droplets or direct contact with infected respiratory tract secretions or urine.|
|Incubation period||About 16 to 18 days, ranging from 12 to 25 days.|
|Period of communicability||From 7 days before the onset of parotitis until 9 days after the onset of illness.|
|Funded vaccine||A live-attenuated vaccine (MMR II), containing measles, mumps and rubella viruses.|
|Funded vaccine indications and schedule||Children at ages 15 months and 4 years. |
Adults who are susceptible to one or more of measles, mumps and rubella.
For (re-)vaccination following immunosuppression (seek specialist advice).
|Vaccine efficacy/effectiveness||64–66 percent effective against laboratory-confirmed mumps after 1 dose and 83–88 percent after 2 vaccine doses.|
|Egg allergy||Egg allergy, including anaphylaxis, is not a contraindication for MMR vaccine.|
|Adverse events to vaccine||MMR vaccine is generally well tolerated. The risk of adverse reactions to MMR vaccine is low, compared to the risk of complications from mumps disease.|